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Abstract  12 
 13 
Millions of naïve T cells with different TCRs may interact with a peptide-MHC ligand, but 14 
very few will activate. Remarkably, this fine control is orchestrated using a limited set of 15 
intracellular machinery. It remains unclear whether changes in stimulation strength alter the 16 
programme of signalling events leading to T cell activation. Using mass cytometry to 17 
simultaneously measure multiple signalling pathways during activation of murine CD8+ T 18 
cells, we found a programme of distal signalling events that is shared, regardless of the 19 
strength of TCR stimulation. Moreover, the relationship between transcription of early 20 
response genes Nr4a1 and Irf8 and activation of the ribosomal protein S6 is also conserved 21 
across stimuli. Instead, we found that stimulation strength dictates the rate with which cells 22 
initiate signalling through this network.  These data suggest that TCR-induced signalling 23 
results in a coordinated activation program, modulated in rate but not organization by 24 
stimulation strength.  25 
 2 
 
Introduction 26 
 27 
Effector differentiation of a naïve CD8+ T cell begins when its T cell receptor (TCR) recognizes 28 
a peptide-MHCI ligand complex. If the interaction is strong enough, a cascade of signalling 29 
events follows that allows the naïve T cell to differentiate and expand into a pool of effector 30 
cells. Signal transduction downstream of the TCR involves a highly diverse network of post-31 
translational protein modifications that ultimately drive transcriptional, translational, 32 
metabolic and cytoskeletal changes in the cell. It is estimated that fewer than 0.01 % of 33 
naïve  CD8+ T cells can recognize a particular foreign peptide-MHCI complex (Jenkins & 34 
Moon, 2012). Despite the diversity of rearranged TCRs on these naïve cells and the 35 
extensive range of antigenic peptides that may be presented, the intracellular machinery 36 
within each naïve T cell is able to sense the strength of the receptor-ligand interaction and 37 
mount an appropriate response.  38 
 39 
Previous work has demonstrated that the strength of stimulation a T cell receives upon 40 
binding a peptide-MHC ligand complex determines its fate in the thymus and its probability 41 
of activating in the periphery. During thymic selection, T cells that weakly recognize self-42 
peptides are retained, while those that strongly recognize self-peptides undergo negative 43 
selection and are removed (Daniels et al., 2006; Hogquist et al., 1994; Juang et al., 2010; 44 
Prasad et al., 2009).  In the periphery, the population response to stimuli of different 45 
strengths can vary in speed, magnitude and phenotype (Denton et al., 2011; King et al., 46 
2012; Moreau et al., 2012; Ozga et al., 2016; Palmer et al., 2016; Zehn et al., 2009). Work 47 
from our group and others indicates that these observations may be explained by the fact 48 
that stimulation strength controls the rate with which individual cells activate 49 
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transcriptional and proliferative processes (Hommel & Hodgkin, 2007; Richard et al., 2018). 50 
This then raises the question, how does stimulation strength impact signalling downstream 51 
of the TCR, and how does this relate to transcriptional activation (R. Balyan et al., 2018)?  52 
 53 
Many previous studies have examined signalling mediators and their coordinated network 54 
during naïve T cell activation (Kannan et al., 2012; Krishnaswamy et al., 2014; G. Voisinne et 55 
al., 2019). Signalling through the TCR (Courtney et al., 2018; Navarro & Cantrell, 2014) 56 
begins with LCK and Fyn-mediated tyrosine phosphorylation of ITAM motifs on the invariant 57 
CD3 subunits. This creates a high affinity binding site for ZAP70, which, upon 58 
phosphorylation and activation, leads to the generation of the LAT-SLP76 signalosome. From 59 
here, signalling activates multiple cascades including MAPK (MEK1/2-ERK1/2), PDK1-PI3K, 60 
calcium, and NFκB (including INBD-p65) pathways, each amplified and propagated via a 61 
series of phosphorylation events or other post-translational modifications. Signal 62 
transduction pathways can be broadly categorized as digital, with distinct ‘on’ or ‘off’ 63 
outcomes, or analogue, giving rise to a graded response (Conley et al., 2016; Zikherman & 64 
Au-Yeung, 2015). In digital signalling, once the threshold for activation is surpassed, an 65 
output signal of constant intensity is produced. In analogue signalling, higher intensity of the 66 
originating stimulus results in a proportionally higher intensity of the output signal.   67 
 68 
Previous work has demonstrated that ligand potency determines the extent of signalling at 69 
various proximal and distal nodes (Palmer et al., 2016; Rosette et al., 2001). Studies focused 70 
on digital signalling nodes showed that stimulation strength affects the percentage of cells 71 
that phosphorylate ERK (Altan-Bonnet & Germain, 2005; J. Das et al., 2009; Tian et al., 72 
2007), PKD2 (Navarro et al., 2014), IκBα and the p65 component of NFκB (Kingeter et al., 73 
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2010). Most of these studies have looked at each signalling molecule separately.  It 74 
therefore remains unclear how ligand potency affects the coordination of signalling 75 
downstream of the TCR in naïve T cells.  76 
 77 
TCR-induced responses are rapid and often transient, and responding cell populations can 78 
be heterogeneous. Single-cell approaches are therefore well-suited to examining this 79 
system. Mass cytometry provides single-cell resolution, uses antibody-mediated 80 
measurements that can detect post-translational signalling protein modifications, and can 81 
achieve high-dimensionality through simultaneous measurement of up to 40 epitopes 82 
(Bandura et al., 2009; Bendall et al., 2011; Lou et al., 2007; Ornatsky et al., 2010) . Previous 83 
mass cytometry studies of T cell signalling have demonstrated that small differences in 84 
proximal signalling molecules are propagated and amplified in downstream targets 85 
(Mingueneau et al., 2014) and that the interplay of ‘activatory’ versus ‘inhibitory’ signalling 86 
components determines the response of effector T cells to different antigen doses 87 
(Wolchinsky et al., 2014). 88 
 89 
In this study, we designed a mass cytometry panel probing surface receptors and elements 90 
of key signalling pathways (Figure 1) to examine the effect of stimulation strength on naïve 91 
CD8+ T cell responses. We used a minimal antigen presentation system to ask how 92 
modulating only the strength of the TCR-pMHC interaction affects signalling pathways 93 
without the influence of variable costimulatory factors or feedback from other cell types. 94 
Our multi-dimensional approach allowed us to determine how ligand potency impacts the 95 
synchronization of multiple parallel pathways. Through simultaneous measurement of S6 96 
phosphorylation and early mRNA transcripts, we also examined the concurrent activation of 97 
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these markers of translational and transcriptional processes. Our data suggest that the 98 
coordination of the TCR-induced signalling pathways that we tested does not vary with 99 
stimulation strength. Instead, strength of stimulation determines the rate with which T cells 100 
initiate this programme. 101 
 102 
 103 
 Results  104 
 105 
Mass cytometry detects active T cell conjugates 106 
 107 
We used the OT-I TCR transgenic mouse on a recombination-activating gene (RAG)-deficient 108 
background as a model for evaluating the impact of stimulation strength on TCR signalling 109 
pathways. In this model, all peripheral CD8+ T cells recognize the ovalbumin peptide 110 
SIINFEKL. Variants of SIINFEKL with altered potency for the OT-I TCR allow manipulation of 111 
the strength of TCR stimulation (Daniels et al., 2006; Hogquist et al., 1994; Hong et al., 2018; 112 
Rosette et al., 2001). In this study, we used the high potency SIINFEKL (N4), intermediate 113 
potency SIITFEKL (T4), and low potency SIIGFEKL (G4) peptides, as well as an unrelated 114 
control peptide, ASNENMDAM (NP68).  115 
 116 
We designed a custom mass cytometry antibody panel to detect five surface markers of T 117 
cell identity and activation, eight phosphorylated signalling proteins with corresponding 118 
total proteins, and IκBα, which is degraded in response to stimulation (Figure 1; Methods). 119 
The antibodies labelled key components of major signalling pathways, including proximal 120 
signalling (pZAP70[Y319]/pSyk[Y352], pSLP76[Y128], pLCK[Y505] and pPLCγ1[Y783]), the 121 
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MAPK pathway (pERK1/2[T202/Y204]), the PDK1-PI3K and mTOR pathways (pAKT[S473], 122 
pS6[S235/S236]), the NFκB pathway (IκBα) and the IL2 pathway (pSTAT5[Y694]). All of these 123 
phosphorylation sites indicate active signalling with the exception of the inhibitory Y505 124 
phosphorylation of LCK (D'Oro & Ashwell, 1999; Marth et al., 1988). Measurement of total 125 
proteins allowed us to determine whether changes in phospho-protein staining were due to 126 
differences in signalling or protein expression levels.  127 
 128 
We isolated naïve CD8+ T cells from OT-I Rag1-/- splenocytes before stimulating with ligands 129 
of various strengths. To monitor signalling while naïve CD8+ T cells transitioned to activated 130 
T cells, and to relate signalling to changes in mRNA and protein expression during this 131 
process, cells were stimulated for 1, 2, 4 and 6 hours. We used a minimal, controlled system 132 
of peptide addition, allowing T cells to present antigens to each other. We also added 133 
exogenous IL2 to mitigate effects of potency-dependent differences in paracrine IL2  (Au-134 
Yeung et al., 2017; Denton et al., 2011; Marchingo et al., 2014; Tan et al., 2017; Verdeil et 135 
al., 2006; Guillaume Voisinne et al., 2015) and provide all cells with an effector-promoting 136 
environment (Pipkin et al., 2010; Verdeil et al., 2006). This system was chosen in order to 137 
examine the cell-intrinsic effects of TCR stimulation strength on signalling pathways. 138 
Peptides were added at 1 µM since peptide titration revealed minimal differences in the 139 
percentage of cells phosphorylating S6 and ERK between 100 nM and 1 µM stimulation 140 
conditions (Figure 2- figure supplement 1). Using this reductionist stimulation system, we 141 
previously found that stimulation strength determined the rate with which naïve T cells 142 
initiated transcriptional activation but that cells activated by all ovalbumin-derived ligands 143 
were proliferating and expressing the effector molecule CD44 by two days (Richard et al., 144 
2018).  145 
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 146 
Stimulated cells were stained with metal-conjugated antibodies and markers for dead cells 147 
and DNA before profiling by mass cytometry. We gated events detected by the mass 148 
cytometer in a hierarchical manner to select single, living cells that were TCRβ+ and CD8α+ 149 
before examining individual signalling molecules (Figure 2a). While gating for single cells 150 
based on DNA content (Figure 2 – figure supplement 2a), we noted that a substantial 151 
percentage of events contained more than one cell-equivalent of DNA, particularly among 152 
cells stimulated with the strongest peptide, N4 (Figure 2 – figure supplement 2b). Separating 153 
events by DNA content revealed two distinct populations, such that events containing two 154 
cell-equivalents of DNA had higher phosphorylated and total protein staining (Figure 2b, 155 
Figure 2 - figure supplement 2c-d). It is therefore likely that this population contained 156 
multiple cells (i.e. doublets), potentially even cells engaged in TCR-peptide-MHC interactions 157 
with their neighbours. After normalization of each phosphorylated protein to the DNA signal 158 
detected in the same mass cytometry event, signal intensities for events with two cell-159 
equivalents of DNA had similar ranges to those of events with one for most markers (Figure 160 
2 – figure supplement 2e). This provided further evidence that events with two cell-161 
equivalents of DNA were doublets. Supporting the hypothesis that these doublets 162 
represented actively conjugated cells, a greater proportion of doublets than singlets showed 163 
signalling behaviour. In addition, from 1 to 4 hours after stimulation, pSLP76 signal was 164 
higher in doublet events even after normalisation, suggesting that SLP76 was preferentially 165 
phosphorylated in cells actively engaged in TCR-peptide-MHC interactions. Because it was 166 
not possible to discern which proteins were signalling in which cell in a multiplet event, for 167 
subsequent analyses we included only singlet events.  168 
 169 
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Ligand potency affects the kinetics of signalling protein activation  170 
 171 
We next examined the kinetics of individual signalling molecules within our mass cytometry 172 
data. Total levels of signalling proteins did not substantially change over a 6 hour 173 
stimulation, while expression of effector proteins CD44 and CD25 increased in a time- and 174 
potency-dependent manner (Figure 3 – figure supplement 1).  In the presence of exogenous 175 
IL2, ligand potency did not strongly influence the rate with which individual cells 176 
phosphorylated STAT5 (Figure 3 – figure supplement 2a). In the absence of exogenous IL2, 177 
STAT5 phosphorylation was associated with ligand potency, such that weak G4-stimulated 178 
cells showed no STAT5 phosphorylation (Figure 3 – figure supplement 2b), likely due to 179 
autocrine/paracrine IL2 rapidly secreted by strongly stimulated cells (Tan et al., 2017). The 180 
percentages of cells degrading INBD or phosphorylating S6 or ERK1/2 were not impacted by 181 
the presence of exogenous IL2. The percentages of cells phosphorylating pAKT[S473] were 182 
subtly increased by IL2 particularly under stimulation with low potency ligands (Figure 3 – 183 
figure supplement 2b). This may reflect the mechanism proposed by Ross et al whereby JAK 184 
signalling induced by IL2 ultimately stimulates mTORC2 phosphorylation of AKT[S473] (Ross 185 
et al., 2016). Together, these data indicate the selectivity of IL2 effects on T cell signalling 186 
pathways.  187 
 188 
Phosphorylation of proximal, membrane-recruited mediators ZAP70 and PLCγ1 was only 189 
detectable in a small percentage of cells at any point during this time course, preventing 190 
further interpretation (Figure 2b). For LCK, the percentage of cells with inhibitory 191 
phosphorylation of pY505 decreased at 6 hours in a potency-dependent manner, suggesting 192 
that stronger stimuli resulted in greater LCK activity only at this late time point (Figure 3 – 193 
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figure supplement 2a). For SLP76, the high potency ligand N4 induced a greater percentage 194 
of signalling cells and greater signalling intensity within these cells between 1 and 4 hours, 195 
whereas signalling was minimal in cells stimulated with intermediate (T4) or low potency 196 
(G4) ligands (Figure 2b, Figure 3 – figure supplement 2a).  197 
 198 
Examination of the kinetics of individual distal signalling molecules revealed two distinct 199 
patterns. We defined these as transient if the percentage of signalling cells increased and 200 
subsequently decreased during the time course of high potency stimulation, and sustained if 201 
maximal signalling was ongoing at 6 hours (Figure 3a). ERK1/2, AKT and IκBα displayed 202 
transient signalling. While ERK1/2 and AKT are phosphorylated in response to TCR 203 
stimulation, IκBα is degraded, releasing NFκB subunits and permitting their translocation to 204 
the nucleus (Paul & Schaefer, 2013). Therefore, a reduction in IκBα+ cells indicates active 205 
signalling by this node. For these three signalling mediators, the percentage of cells actively 206 
signalling was maximal at 2 hours when stimulated with the highest potency N4 peptide but 207 
was delayed until 4 or 6 hours when stimulated with the lower potency T4 or G4 peptides 208 
(Figure 3a). After 2 hours, signalling via these proteins declined in strongly stimulated cells, 209 
resulting in a convergence with more weakly stimulated cells. In addition, the maximum 210 
percentage of cells signalling through these nodes was substantially higher in strongly 211 
stimulated cells. This may indicate repeated node activation after high potency stimulation, 212 
such that a greater proportion of cells were signalling at any given time of measurement. 213 
Thus, for these transiently signalling proteins, ligand potency was associated with the 214 
maximal proportion of signalling cells and the speed with which this proportion was reached 215 
on a populational level.  216 
 217 
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In contrast to these transient signalling events, S6 phosphorylation induced by TCR 218 
stimulation was sustained within our time course (Figure 3a). Under N4 stimulation, there 219 
was a rapid initial increase in the percentage of pS6+ cells before a plateau. This pattern may 220 
be indicative of the signalling protein approaching saturation. The appearance of pS6+ cells 221 
was slower after stimulation with lower potency ligands, but the proportions of pS6+ cells 222 
approached convergence between N4, T4 and G4 stimulations at 6 hours. Thus, for S6, the 223 
rate with which cells exhibited active signalling, but not the maximal proportion of signalling 224 
cells was associated with ligand potency. 225 
 226 
We observed a bimodal distribution of pERK1/2 measurements in our mass cytometry data, 227 
consistent with previous reports (Altan-Bonnet & Germain, 2005; J. Das et al., 2009; Tian et 228 
al., 2007). The extent of ERK1/2 phosphorylation in pERK1/2+ cells, as determined by the 229 
median marker intensity, was unaffected by ligand potency (Figure 3 – figure supplement 230 
3a). This confirmed that ERK1/2 exhibits digital signalling behaviour, i.e. on a per cell basis 231 
there is either an ‘on’ or ‘off’ state. Similarly, pS6[S235/S236] signal was also bimodally 232 
distributed (Figure 2a, Figure 3 – figure supplement 3b). The intensity of pS6 signal in pS6+ 233 
cells slightly increased over time. Normalization to total S6 protein intensity mitigated this 234 
effect (particularly under strong stimulation) and suggested that ligand potency may subtly 235 
affect the rate of S6 phosphorylation within individual cells (Figure 3 – figure supplement 3c) 236 
in addition to the percentage of pS6+ cells at early time points.  237 
 238 
Since S6 phosphorylation at S235/S236 is driven by both S6K1 downstream of mTORC1, and 239 
RSK downstream of MEK1/2-ERK1/2 (Pende et al., 2004; Roux et al., 2007; R. J. Salmond et 240 
al., 2009), we were interested in how each of these pathways contributed to its digital 241 
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behaviour in strongly stimulated cells. To this end, we treated cells with inhibitors of 242 
MEK1/2 (MEK162 (Lee et al., 2010),  Figure 3 – figure supplement 3d) and mTOR (rapamycin 243 
(Pollizzi & Powell, 2015)) before stimulation with N4 peptides. The per-cell phosphorylation 244 
of S6 decreased moderately in response to rapamycin (Figure 3b-c), with little difference 245 
between doses of 20 nM and 2 μM (Figure 3 – figure supplement 3e), but the bimodal 246 
distribution of pS6 and the percentage of pS6+ cells were not disturbed. In contrast, while S6 247 
phosphorylation also decreased within each cell in response to MEK162, this response was 248 
dose-dependent between 0.5 and 5 PM, and at the highest dose (5 μM), the bimodality was 249 
disturbed. In addition, even low doses of MEK162 halved the percentage of cells with 250 
phosphorylated S6 (Figure 3d). Combined MEK162 and rapamycin resulted in severe 251 
inhibition of S6 phosphorylation (Figure 3b). Neither MEK162, rapamycin, nor the 252 
combination of these two substantially impacted CD44 expression at the concentrations of 253 
inhibitors used (Figure 3 – figure supplement 3f), but a synergistic inhibition of cellular 254 
proliferation was observed after 2 days (Figure 3 – figure supplement 3g).  Thus, 255 
simultaneous activity of the MEK and mTOR pathways is required for phosphorylating 256 
S6[S235/S236] and proliferative responses, and MEK signalling is essential for S6 digital 257 
phosphorylation. These data emphasize the coordinated nature of signalling downstream of 258 
the TCR. 259 
 260 
Ligand potency determines the abundance of signalling cells but not the coordination of 261 
signalling events 262 
 263 
To take advantage of the simultaneous measurements in mass cytometry data, we next 264 
tested for differential abundance of multidimensional cellular phenotypes, taking into 265 
 12 
 
account all of the signalling markers measured (A. T. L. Lun et al., 2017) (Figure 4a, Figure 4 - 266 
figure supplement 1). We first defined 1585 fine-grained phenotypic states in the high 267 
dimensional space. We then compared the abundance of cells within these phenotypic 268 
states between unstimulated and all stimulated conditions (Methods). Clustering of 269 
significantly differentially abundant states revealed two main signalling phenotypes. 270 
Phenotype A, defined as pS6+ pSTAT5+ pERK1/2+, was most prevalent in the high potency 271 
(N4)-stimulated cells. Phenotype B, defined as pS6+ pSTAT5+ pERK1/2-, appeared under all 272 
stimulation conditions with uniform prevalence (Figure 4a). Phenotypes A and B were 273 
paralleled by the pSTAT5- phenotypes A’ and B’, respectively. Phenotypes A and A’ were 274 
transient, whereas phenotypes B and B’ were sustained. Subpopulation analysis confirmed 275 
that the high potency ligand N4 was capable of inducing a greater abundance of phenotypes 276 
A’ (pS6+ pSTAT5- pERK1/2+) and A (pS6+ pSTAT5+ pERK1/2+) up to 4 hours after stimulation 277 
(Figure 4b). In contrast, abundances of phenotypes B (pS6+ pSTAT5+ pERK1/2-) and B’ (pS6+ 278 
pSTAT5- pERK1/2-) increased at a similar rate between 1 and 6 hours after stimulation with 279 
all ovalbumin-derived ligands and were not associated with ordered ligand potency.  280 
 281 
To complement these signalling phenotypes, we further investigated their relationship with 282 
surface expression of the effector protein CD44, which was an important contributor to 283 
phenotypic cluster separation (Figure 4a). We examined the 16 (24) possible states defined 284 
by combinations of the markers CD44, pS6, pSTAT5 and pERK1/2. The strongest peptide, N4, 285 
was capable of inducing a large proportion of CD44- pS6+ pSTAT5- pERK+ cells after 1 hour of 286 
stimulation (Figure 4c, Figure 4 - figure supplement 2). This was accompanied by an 287 
increasing population of CD44- pS6+ pSTAT5+ pERK+ cells, which reached its maximum 288 
abundance 2 hours after stimulation. Cells stimulated by the weaker peptides T4 and G4 289 
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showed dramatically reduced abundances of these cellular phenotypes, and their maxima 290 
were delayed. For all stimuli, a high abundance of CD44- pS6+ pSTAT5+/- pERK1/2- cells was 291 
seen between 4 and 6 hours. Cells expressed CD44 by 4 hours after strong and intermediate 292 
stimulation (N4 and T4) and by 6 hours after weak stimulation (G4).  293 
 294 
From these data, we inferred the coordination of distal TCR-induced signalling. We propose 295 
that within our stimulation system, activating cells initially phosphorylate S6 and ERK1/2, 296 
followed by STAT5, after which ERK1/2 becomes dephosphorylated, followed by STAT5 in 297 
some cells. In the early hours after stimulation, signalling cells express CD44 at the same 298 
level as unstimulated cells but begin upregulating CD44 expression by 4-6 hours. As time 299 
progresses and cells shift to sustained phenotypes, those activated with reduced potency 300 
stimuli begin to phenotypically resemble those stimulated with high potency ligand (Figure 301 
5). To formally test this order of activation events, we constructed activation trajectories of 302 
cells under each stimulation condition across all time points, based on their expression of 303 
pS6 (Figure 5 – figure supplement 1a). We then asked in what order along these trajectories 304 
pS6, pERK1/2, pSTAT5, and CD44 activation events were initiated (Figure 5 – figure 305 
supplement 1b-c). We found that pS6 appeared first, followed by pERK1/2, pSTAT5, and 306 
finally CD44. Of note, the start of ERK1/2 phosphorylation corresponded to the most 307 
dramatic increase in S6 phosphorylation, supporting evidence that ERK activation drives full 308 
S6[S235/S236] phosphorylation (Figure 3). The order of activation events was shared across 309 
stimulation conditions (p = 0.00174 compared to random orders of events, Methods). The 310 
signalling molecules pAKT, pLCK and INBD were less dynamic along the trajectory, 311 
precluding precise determination of their order of activation particularly in weakly 312 
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stimulated cells, but visualizing their changes along the trajectory further suggested shared 313 
patterns between stimuli (Figure 5 – figure supplement 1d). 314 
 315 
We therefore conclude that ligand potency controls the rate with which cells achieve certain 316 
signalling states and that the order of these signalling events is preserved regardless of 317 
stimulation strength. 318 
 319 
Biosynthetic pathways are coordinately regulated downstream of TCR activation 320 
 321 
Finally, we shifted our focus further downstream to examine the relationship between 322 
signalling at the ribosomal protein S6 and mRNA expression of early response transcription 323 
factors. These two activation events indicate initiation of translational and transcriptional 324 
processes, which are required for the biosynthetic programs of T cell activation (Araki et al., 325 
2017; Howden et al., 2019; Tan et al., 2017). S6 is a ribosomal protein whose 326 
phosphorylation reflects, though it does not regulate, TCR-induced translation (R. J. 327 
Salmond et al., 2015; R. J. Salmond et al., 2009). Nr4a1 (Nur77) and Irf8 encode 328 
transcription factors that are rapidly expressed upon T cell activation (Moran et al., 2011; 329 
Nelson et al., 1996), and we previously found that their transcripts are upregulated at 1 and 330 
3 hours, respectively, after strong N4 stimulation (Richard et al., 2018) (Figure 6 – figure 331 
supplement 1a). To examine these translational and transcriptional characteristics 332 
simultaneously, we activated naïve OT-I CD8+ T cells with ligands of various potencies before 333 
measurement of pS6 and mRNA molecules using combined phosphoflow and RNA flow 334 
cytometry (Figure 6a, Figure 6 - figure supplement 1b).  335 
 336 
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Stimulation time courses with the different potency ligands suggested that Nr4a1 337 
transcripts were upregulated before phosphorylation of S6 and downregulated after, while 338 
Irf8 transcripts were upregulated after S6 phosphorylation (Figure 6b, Figure 6 - figure 339 
supplement 1c). This order of events appeared consistent across stimuli. The percentage of 340 
pS6+Nr4a1+ cells was maximal between 1 and 2 hours after stimulation with the highest 341 
potency peptide N4, after 4 hours stimulation with the intermediate potency peptide T4, 342 
and after 6 hours stimulation with the lowest potency peptide G4. Likewise, the percentage 343 
of pS6+Irf8+ cells was maximal after 2 hours stimulation with N4, 4 hours stimulation with T4 344 
and 6 hours stimulation with G4 peptides (Figure 6b). Similar to the multi-dimensional 345 
signalling phenotypes we measured by mass cytometry, these altered kinetics of 346 
phosphorylation and transcript upregulation indicate that stimulation strength controls 347 
their rate of activation.  348 
 349 
These results suggest that the relationship between signalling events is conserved under 350 
different strengths of stimulation, even among differing signal transduction pathways 351 
controlling transcription and translation. Upon TCR activation both the transcriptional and 352 
translational machinery are deployed in a coordinated manner, which may improve 353 
efficiency of protein production enabling the naïve CD8+ T cell to differentiate and 354 
proliferate. 355 
 356 
Ligand potency affects the kinetics of selected signalling proteins in the presence of 357 
professional antigen-presenting cells 358 
 359 
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The interaction of adhesion molecules LFA-1 and ICAM-1 assists the formation of a stable 360 
immunological synapse, augments TCR-induced signalling, and continues to promote 361 
differentiation even after initial activation (Gérard et al., 2013; Verma & Kelleher, 2017). 362 
LFA-1 is constitutively expressed by naïve T cells, and TCR stimulation drives both 363 
redistribution and conformational changes that enhance its binding to the ligand ICAM-1 364 
(Capece et al., 2017; Dustin & Springer, 1989; Verma & Kelleher, 2017). Palmer et al 365 
previously demonstrated that LFA-1-ICAM-1 interactions improve conjugate formation 366 
during T cell stimulation with peptide-loaded splenocytes, particularly for low potency 367 
ligands (Palmer et al., 2016). However, it remained unclear whether ICAM-1 was expressed 368 
in our stimulation system and whether this integrin interaction could thereby play a role. 369 
We therefore measured ICAM-1 on the surface of T cells 6 hours after addition of pure 370 
peptides of various potencies (Figure 7 – figure supplement 1a) and found that all T cells 371 
expressed ICAM-1, regardless of their stimulation status. These data suggest that integrin 372 
adhesion likely contributes to T cell activation along with TCR stimulation and exogenous IL2 373 
in our system. 374 
 375 
In contrast to this reductionist system, many additional factors impact T cell activation in 376 
vivo. Most fundamentally, naïve T cells are activated in the lymph node by professional 377 
antigen-presenting cells (APCs), such as dendritic cells, instead of other T cells. These APCs 378 
express costimulatory ligands in addition to peptide-MHC complexes, which can further 379 
tune naïve T cell responses (L. Chen & Flies, 2013; Hubo et al., 2013). For example, in our 380 
stimulation system, the costimulatory ligand CD80 remained largely absent after 6 hours of 381 
stimulation (Figure 7 – figure supplement 1a). In contrast, mature bone marrow-derived 382 
dendritic cells (BMDCs) expressed high levels of CD80, along with additional costimulatory 383 
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molecules (Figure 7 – figure supplement 1b). To test how signalling responses to ligands of 384 
different strengths might be impacted by the additional signalling conferred by professional 385 
APCs, we stimulated naïve T cells with mature BMDCs (Figure 7 – figure supplement 1b-c) 386 
loaded with peptides of various potencies. Exogenous IL2 was included to maintain 387 
comparability with the T:T stimulation system. Signalling molecules pZAP70, pSLP76, 388 
pERK1/2, pS6 and pSTAT5, as well as CD44 expression, were measured by flow cytometry.  389 
 390 
We found that activation was in general less strong in the presence of peptide-pulsed 391 
professional APCs than pure peptides (Figure 7), perhaps due to reduced ligand availability 392 
as only half of the cells in the culture carried ligand (Methods). The potency-dependent 393 
kinetics of pERK1/2, pSLP67 and CD44 resembled those observed in the T:T stimulation 394 
system, while pZAP70 remained undetectable. pS6 was upregulated over time under 395 
stimulation with high, medium and low potency ligands. pSTAT5 was upregulated over time 396 
with all stimuli, including the null peptide NP68, suggesting that simply mixing naïve T cells 397 
with BMDCs enhanced IL2 signalling. These results indicate that the rate-based mechanism 398 
we observed in the T:T stimulation system is further tuned at particular signalling nodes by 399 
more complex antigen presentation.   400 
 401 
Discussion 402 
 403 
In this study, we examined the coordination of signalling pathways downstream of TCR 404 
activation using a custom mass cytometry panel as well as protein and RNA flow cytometry. 405 
The use of multidimensional measurements allowed us to probe the simultaneous 406 
activation of multiple signalling and transcriptional processes. This enabled comparisons of 407 
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the impact of ligand potency on not only individual activation events but also their 408 
coordination. We found that the strength of TCR stimulation controlled the rate of 409 
appearance of the multi-dimensional signalling and transcriptional phenotypes that we 410 
profiled.  411 
 412 
Stimulation strength altering the rate of T cell activation has been observed in previous 413 
studies from our group and others investigating transcriptomic, proliferation, and protein 414 
expression characteristics (Hommel & Hodgkin, 2007; Richard et al., 2018; Rosette et al., 415 
2001). Taken together, these data suggest that by controlling the probability that a cell will 416 
initiate activation responses, signal strength can modulate the average speed and 417 
magnitude of a population response. Our signalling results indicate that if such an activation 418 
switch exists, it lies very proximal to the TCR. 419 
 420 
An important outstanding question is the mechanism by which the TCR translates ligand 421 
strength into the probability of downstream signalling. One model explaining the threshold 422 
for T cell response that could propagate to a rate-based mechanism is kinetic proofreading 423 
(McKeithan, 1995). This theory postulates that the ligand must remain bound to the 424 
receptor for sufficient time for signalling accumulation to surpass a critical event and 425 
propagate downstream. Indeed, multiple reports have suggested that naïve T cells require 426 
sustained interaction with presented antigen to achieve optimal proliferation, though the 427 
necessary duration differs by study and likely depends on the presence of additional factors 428 
such as IL2 (Renu Balyan et al., 2017; Curtsinger et al., 2003; Iezzi et al., 1998; Kaech & 429 
Ahmed, 2001; Prlic et al., 2006; van Stipdonk et al., 2003; van Stipdonk et al., 2001; Wong & 430 
Pamer, 2001). Refinements to the kinetic proofreading model suggest that not a single 431 
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interaction but rather the cumulative interaction lifetime of a series of early binding events 432 
controls signal accumulation (Dushek et al., 2009; Liu et al., 2014). Biophysical investigations 433 
of the impact of force on binding events between the TCR and pMHC (as well as CD8) have 434 
described catch bonds formed with high potency ligands that extend interaction lifetimes 435 
(D. K. Das et al., 2015; Hong et al., 2018; Liu et al., 2014; Sibener et al., 2018; P. Wu et al., 436 
2019), though this observation has not been universal (Limozin et al., 2019) and merits 437 
further investigation. Extrapolating from this lifetime theory, altered ligand potency could 438 
change the probability of long or rapidly repeated binding events, thereby controlling the 439 
probability that an individual cell activates.  440 
 441 
If such a lifetime-based mechanism exists, T cells must then translate variation in binding 442 
lifetime to the presence or absence of downstream signalling. Palmer and colleagues found 443 
ligand potency-associated differences in CD3ζ chain and ZAP70 phosphorylation (Daniels et 444 
al., 2006; Palmer et al., 2016), which may allow potency-dependent accumulation of signal 445 
before propagation downstream. Supporting this hypothesis, John James demonstrated that 446 
the number of CD3 ITAM motifs in a synthetic receptor influenced the rate but not the 447 
magnitude of signalling within individual Jurkat cells (James, 2018). Likewise, 448 
Mukhopadhyay et al. found that the presence of multiple ζ chain ITAMs, as well as ZAP70, 449 
increases the efficiency of phosphorylation in a HEK 293T cell reconstitution system, 450 
although these phosphorylation events do not account for the apparent switch-like 451 
ultrasensitive behaviour of T cell signalling (Mukhopadhyay et al., 2016). One mechanism 452 
that could explain the switch-like behaviour is the zero-order ultrasensitivity model (Ferrell 453 
& Ha, 2014; Goldbeter & Koshland, 1981), wherein negative regulators act in combination 454 
with activators to enhance responsiveness when signalling molecules operate close to 455 
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saturation. In this way, a relatively small change in the binding lifetime of a pMHC ligand 456 
could be amplified by altering a kinase/phosphatase ratio to switch between the presence 457 
and absence of downstream signalling. An alteration in the local relative abundances of 458 
phosphatase CD45 and kinase LCK described by the kinetic segregation model (Davis & van 459 
der Merwe, 2006; Razvag et al., 2018) represents an intriguing candidate for controlling a 460 
zero-order ultrasensitivity mechanism (Hui & Vale, 2014), although a subsequent study has 461 
refuted its requirement for T cell activation (Al-Aghbar et al., 2018), suggesting other 462 
mechanisms. Control may also be mediated by the phosphatase PTPN22, which can 463 
dephosphorylate CD3ζ chains, ZAP70 and LCK (J. Wu et al., 2006), as absence of PTPN22 464 
results in increased proportions of activated cells, particularly under weak stimulation 465 
(Robert J Salmond et al., 2014). Alternatively, Lo et al. showed that the slow 466 
phosphorylation of a tyrosine residue in LAT is a possible candidate for this rate-limiting 467 
step, since substitution of a single residue that enhances this phosphorylation improves T 468 
cell response to low potency ligands (Lo et al., 2019). 469 
 470 
Through our single-cell measurements, we confirmed (Altan-Bonnet & Germain, 2005; J. Das 471 
et al., 2009; Tian et al., 2007) that ERK1/2 is phosphorylated with ‘on or off’ states, 472 
characteristic of digital signalling. In addition, we found that S6[S235/S236] is also 473 
phosphorylated in a similar manner. However, whilst the extent of ERK1/2 phosphorylation 474 
during the “on” state was constant, the extent of S6 phosphorylation subtly increased both 475 
with time and strength of stimulus. The parallel subtle increase in total S6 expression over 476 
time implies induction of S6 protein production during T cell activation. These data suggest 477 
that dividing signalling proteins into digital or analogue can be complicated by changes in 478 
total protein levels that may attribute analogue properties to a digital signal.  479 
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 480 
Previous work has shown that in addition to mTORC1 signalling, the MEK/ERK pathway 481 
contributes to S6[S235/S236] phosphorylation (Pende et al., 2004; Roux et al., 2007), 482 
particularly in naïve T cells (Krishnaswamy et al., 2014). Therefore, combinatorial effects of 483 
mTORC1 and MEK signalling might be expected to influence both S6 phosphorylation and 484 
other downstream T cell activation phenotypes. We found that chemical inhibition of both 485 
of these pathways blocked S6 phosphorylation, implying that they contribute in a non-486 
redundant manner. A dose titration with MEK162 indicated that MEK/ERK signalling is 487 
critical for phosphorylation of S6[S235/S236]. Even at low doses, MEK162 reduced the 488 
percentage of pS6+ cells, suggesting that it may modulate the rate of response. 489 
Furthermore, in our trajectory analysis of multiple signalling markers, a steep increase in S6 490 
phosphorylation coincided with the appearance of pERK+ cells under all peptide stimuli 491 
(Figure 5 – figure supplement 1a-b). These data raise the possibility that digital 492 
phosphorylation of ERK propagates through RSK to S6[S235/S236].  493 
 494 
We additionally explored the effects of rapamycin and MEK162 on naïve T cell proliferation. 495 
Although rapamycin had little effect on S6 phosphorylation, it had a profound effect on T 496 
cell proliferation, which may be due to several different mechanisms. First, rapamycin can 497 
also impact mTORC2 signalling after prolonged treatment (Sarbassov et al., 2006), and naïve 498 
T cells may be particularly susceptible (Delgoffe et al., 2011). Second, mTORC1 affects many 499 
additional pathways other than ribosomal activity (Pollizzi & Powell, 2015; R. J. Salmond, 500 
2018). Finally, even when signalling through S6K1, mTORC1 can influence proliferation 501 
through pS6-independent mechanisms (R. J. Salmond et al., 2015). We also found that MEK 502 
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inhibition with MEK162 synergized with rapamycin to further dampen T cell proliferation, 503 
highlighting the interconnected nature of the signalling pathways downstream of the TCR.   504 
 505 
Many signalling molecules exhibited transient behaviour at the population level (ERK1/2, 506 
IκBα, AKT), while pS6 accumulated over the course of our 6-hour experiments. Stimulation 507 
strength strongly influenced the proportion of cells exhibiting transient signalling behaviours 508 
between 1 and 4 hours after activation, but by 6 hours, cells activated with any of the 509 
ovalbumin-derived peptide ligands exhibited a similar signalling phenotype. This potency-510 
dependent difference in the maximal proportions of cells signalling may be due to either 511 
repeat or sustained signalling with strong ligands, the latter of which has been observed for 512 
calcium fluxes induced by TCR stimulation (J. L. Chen et al., 2010; Le Borgne et al., 2016; 513 
Wulfing et al., 1997). For example, although under weak G4 stimulation only a very small 514 
percentage (15.4%) of cells were found to be pERK1/2+ at any given time, the majority 515 
(72.1%) of G4-stimulated cells achieved digital activation of pS6[S235/236] by 6 hours 516 
(Figure 3a). Given that we found full S6 phosphorylation after strong stimulation requires 517 
MEK signalling, we hypothesize that this pathway is active in all stimulation conditions but 518 
that ERK activation events occur with reduced frequency or duration with weak stimuli and 519 
thus many were missed in our snapshot measurements. Future investigations using ERK 520 
reporters and ERK inhibition in weakly stimulated cells would be needed to test this 521 
prediction. Consistent with this proposed mechanism, single-cell studies in epithelial and 522 
HEK293 cell lines have observed oscillating ERK phosphorylation with frequency and 523 
duration dependent on the concentration or frequency of EGF stimulation (Albeck et al., 524 
2013; Ryu et al., 2018). Such an effect on digital ERK activation may be modulated by multi-525 
step activation of the upstream mediator SOS dependent on its dwell-time after activation-526 
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induced recruitment to the plasma membrane (Huang et al., 2019). Interestingly, using a 527 
light-inducible ERK activation system in epithelial cells, Aoki et al demonstrated divergent 528 
transcriptional effects of sustained versus transient ERK activation (Aoki et al., 2013). It 529 
therefore remains possible that different ERK targets in T cells, such as translational 530 
machinery, microtubule remodelling, and transcription factors (e.g. ELK1, SAP1, SAP2) 531 
(Navarro & Cantrell, 2014) are differentially affected by stimulation strength, warranting 532 
further investigation of additional downstream components. 533 
 534 
Examination of the coordinated activation of transcriptional and translational signalling 535 
pathways also revealed conservation of this order of events. Biosynthetic processes are 536 
critical for naïve T cells to differentiate into effector cells (Araki et al., 2017; Tan et al., 537 
2017), and thus, carefully controlled simultaneous activation would ensure efficient, 538 
consistent effector differentiation of activated cells.   539 
 540 
Under stimulation with peptide-loaded BMDCs, ligand potency determined the percentages 541 
of T cells undergoing certain activation events (pERK1/2, pSLP76 and CD44), similar to 542 
observations in our reductionist stimulation system. In contrast, phosphorylation of S6 was 543 
not associated with ligand potency after stimulation with peptide-loaded BMDCs. Unlike 544 
naïve and recently activated T cells, BMDCs express high levels of costimulatory molecules 545 
that can impact TCR-induced signalling. For example, ligation of the costimulatory receptor 546 
CD28 at the same time as the TCR results in amplification of signalling pathways including 547 
NFAT, NFNB and AP-1, and can enhance both the sensitivity and ultimate division potential 548 
of naïve T cell activation (Esensten et al., 2016; Heinzel et al., 2017; Marchingo et al., 2014; 549 
Yang et al., 2017). Further exploration of how individual costimulatory ligands impact the 550 
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coordination and initiation rate of the TCR-induced signalling programme will be important 551 
for dissecting these additional inputs. 552 
 553 
Despite the increased complexity of BMDC peptide presentation, this in vitro system is 554 
nevertheless still far-removed from in vivo T cell activation, where the microenvironment is 555 
increasingly complex.  Additional variables such as cytokine and nutrient availability and 556 
cell-cell interactions can further tune the T cell response in vivo (Curtsinger & Mescher, 557 
2010; Kedia-Mehta & Finlay, 2019). Moreover, strongly stimulated T cells undergo 558 
prolonged retention in the lymph node (Ozga et al., 2016; Zehn et al., 2009) and may out-559 
compete weakly stimulated T cells for cytokines and nutrients (Wensveen et al., 2012), 560 
suggesting that stimulation strength and the microenvironment are not independent. Our 561 
controlled in vitro systems allowed us to identify effects of stimulation strength on TCR-562 
induced pathways alone, as well as in the context of BMDC-mediated costimulation, without 563 
confounding by other in vivo factors and feedback. By delineating the impact of stimulation 564 
strength in low-complexity systems, these data can form the basis for interpretation of 565 
future studies where additional variables may be explored. 566 
 567 
In this study, we measured 22 markers of protein expression and active signalling. While 568 
other unmeasured signalling mediators may respond to altered stimulation strength in a 569 
different manner, our data demonstrate a strict choreography of the distal signalling 570 
processes that we examined. Stimulation strength was associated with the rate with which 571 
cells embarked on this regimented programme. This suggests that using a limited set of 572 
signalling machinery in a single coordinated programme, T cells can finely tune their 573 
responses to different ligands through modulation of the rate of signalling.   574 
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Methods 575 
 576 
Key Resources 577 
 578 
Key resources are detailed in Supplementary File 2. 579 
 580 
Ethics 581 
 582 
Animal experimentation: Experiments were carried out under Project Licence PPL 70/8590. 583 
This research has been regulated under the Animals (Scientific Procedures) Act 1986 584 
Amendment Regulations 2012 following ethical review by the University of Cambridge 585 
Animal Welfare and Ethical Review Body (AWERB). 586 
 587 
Mice 588 
 589 
CD8+ T cells were isolated from OT-I Rag1-deficient mice (OT-I Rag1tm1Bal on a C57BL/6 590 
background), which underwent confirmation of genotype prior to study. BMDCs were 591 
generated from wild-type C57BL/6 mice. Experiments used both male and female mice 9-25 592 
weeks old. Mice were bred and maintained within University of Cambridge animal facilities.  593 
 594 
Cell culture and stimulation 595 
 596 
For T cell isolation, single cell suspensions of splenocytes were produced via 597 
homogenization of the spleen through a 70 µM nylon strainer.  CD8+ T cells were isolated 598 
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using the Mouse CD8D+ T cell Isolation Kit (MACS Miltenyi Biotec).  Cells were cultured in 599 
RPMI 1640 (Gibco), 10% FBS (Biosera), penicillin-streptomycin (Sigma), sodium pyruvate 600 
(Gibco), L-glutamine (Sigma), β-mercaptoethanol (Gibco) and 20 ng/ml recombinant mouse 601 
IL-2 (Peprotech). For stimulation, the following peptides were used at the concentrations 602 
indicated: SIINFEKL (N4), SIITFEKL (T4), SIIGFEKL (G4), and ASNENMDAM (NP68) (Cambridge 603 
Bioscience).   604 
 605 
Bone marrow derived dendritic cells (BMDCs) were generated based on a published 606 
protocol by Abcam. Femurs and tibias were sterilized in 70 % ethanol and flushed with cold 607 
BMDC culture media, consisting of RPMI 1640 (Gibco), 10 % FBS (Biosera), penicillin-608 
streptomycin (Sigma), L-glutamine (Sigma) and β-mercaptoethanol (Gibco). The suspension 609 
of bone marrow progenitor cells was passed through a 70 µM nylon strainer and plated in 610 
10 cm petri dishes in BMDC culture media supplemented with 20 ng/ml GM-CSF 611 
(Peprotech). Fresh BMDC culture media with 20 ng/ml GM-CSF was added on day 3 and 612 
replaced on day 6 and, if needed, day 8. Immature dendritic cells were harvested from day 7 613 
to day 9. Maturation was induced by culturing immature dendritic cells for 1 day in BMDC 614 
culture media with 20 ng/ml GM-CSF, as well as 50 ng/ml LPS (Thermofisher Scientific) and 615 
20 ng/ml IL4 (Abcam). Differentiation into immature and mature BMDCs was verified by 616 
flow cytometry. To stimulate T cells, mature BMDCs were pulsed with 1 µM of peptide for 1 617 
hour at 37 qC, washed, mixed with naïve T cells at a ratio of 1:1, and cultured for the times 618 
indicated. 619 
 620 
Mass cytometry  621 
 622 
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Purified naïve CD8+ T cells were analysed by mass cytometry. In experiment 1, cells from 4 623 
age-matched mice (2 males and 2 females) were used, representing 4 biological replicates.  624 
In experiment 2, more stimulation conditions were included. This necessitated more cells 625 
for each biological replicate than could be obtained from a single mouse. Therefore, each 626 
biological replicate (1 male, 1 female) was composed of cells from a pair of age- and gender-627 
matched mice. Staining for mass cytometry was performed using sequential MaxPar reagent 628 
kits (Fluidigm) in the following steps. Live cells were stained with 5 µM Cell-ID Cisplatin for 5 629 
minutes at 37°C and rested for 15-30 minutes before stimulation with 1 µM N4, T4, G4, or 630 
NP68 peptides, or left unstimulated. In Experiment 1, cells were stimulated for 1 and 2 631 
hours. In Experiment 2, cells were stimulated for 1, 2, 4 and 6 hours. See Supplementary File 632 
1 for replicate structure. Cells were fixed with Maxpar Fix I Buffer for 10 minutes at room 633 
temperature. Cells stimulated under different conditions were barcoded using the Cell-ID 634 
20-Plex Pd Barcoding Kit and pooled for staining to minimise confounding technical 635 
differences. In experiment 1, all cells from each mouse were pooled into a batch. In 636 
experiment 2, in addition to pooling within a biological replicate, 4 samples were shared 637 
across the two pools to enable batch normalization for differential abundance analysis as 638 
described below. Cells were blocked with FCR blocking reagent (Biolegend, clone 93) and 639 
stained with metal-conjugated surface antibodies (Supplementary File 3). Surface-stained 640 
cells were permeabilised with methanol (Fisher Scientific) and stained with metal-641 
conjugated antibodies against intracellular targets (Supplementary File 3), all diluted in 642 
Maxpar Cell Staining Buffer. Stained cells were then fixed with 1.6 % formaldehyde 643 
(Thermofisher) and stained overnight with 125 nM Cell-ID Intercalator-Ir in Maxpar Fix and 644 
Perm Buffer. Cells were analysed on a Helios CyTOF system (Fluidigm). Data within each cell 645 
pool was normalized and debarcoded using the Fluidigm CyTOF software.   646 
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 647 
Mass cytometry antibodies 648 
 649 
Metal-conjugated antibodies were custom-conjugated where not already commercially 650 
available (Supplementary File 3).  All custom-conjugated antibody clones were tested using 651 
phosphoflow cytometry before and after metal-conjugation. When allocating metals to 652 
antibody targets, brighter metals were assigned to antibodies that exhibited weaker 653 
phosphoflow staining or to those without clear bimodal expression. Metal channels that 654 
receive significant cross-over from other channels were also allocated antibodies with 655 
stronger signals. For each protein target, antibodies against the total protein and its 656 
phosphorylated version were conjugated to metals differing by more than one mass unit to 657 
avoid spillover. 658 
 659 
Antibodies targeting phosphorylated proteins were validated using phosphoflow (with and 660 
without metal conjugation) under different stimulating conditions, including anti-CD3 661 
coated plate (1 µg/ml, BD Biosciences, clone 145-2C11), PMA (50 nM, Sigma-Aldrich) and 662 
ionomycin (1 µg/ml, Sigma-Aldrich), N4 peptide (1 µM), and pervanadate (1 mM, prepared 663 
using sodium orthovanadate, Sigma-Aldrich) (Supplementary File 4). To confirm the 664 
specificity of the antibody clones targeting ZAP70, LCK and SLP76, we transfected HEK 293T 665 
cells, which lack endogenous expression of these proteins, with vectors encoding the 666 
proteins and tested antibody binding via flow cytometry and immunofluorescence 667 
(Supplementary File 4a). To confirm the specificity of the antibody clone targeting PLCγ1 668 
(3H1C10), we performed siRNA knockdown in T cells and tested antibody binding by flow 669 
cytometry (Supplementary File 4a). (Knockdown was validated by western blotting with a 670 
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WB-specific antibody clone (D9H10).) Further validation of phospho-specific antibodies was 671 
performed using signalling inhibitors as detailed in the antibody specificity tables 672 
(Supplementary File 4). 673 
 674 
All metal-conjugated antibodies were tested by mass cytometry prior to experimentation. 675 
By testing antibodies on fixed cells, fixed and barcoded cells, and live cells (surface markers 676 
only), we confirmed there was no additional loss of antibody activity through the addition of 677 
the barcoding step. Two surface markers performed less well when fixed (CD62L-160Gd 678 
clone MEL-14 and CD69-143Nd clone H1.2F3, both Fluidigm). The CD62L-160Gd antibody 679 
was excluded from the mass cytometry panel. The CD69-143Nd antibody was excluded from 680 
the analyses in experiment 1, and excluded from the staining panel in experiment 2. All 681 
metal-conjugated antibodies were titrated for optimal performance and key signalling 682 
antibodies were tested in a time-course assay under different stimulatory conditions to 683 
determine the optimal times for running the full panel.  684 
 685 
Mass cytometry data analysis 686 
 687 
For mass cytometry analysis in FlowJo (v10), debarcoded samples were gated in a 688 
hierarchical manner: EQ bead exclusion followed by selection of intact cells based on DNA 689 
content, single cells based on the event length and DNA content, living cells based on 690 
cisplatin staining, and finally CD8D+ TCRE+ cells. For activation-induced markers, 691 
positive/negative status was defined based on comparison with unstimulated cells. 692 
 693 
 30 
 
Normalization of antibody-measured signals to DNA signal, as well as phospho-protein to 694 
total protein signals, was performed in R using the ncdfFlow (v2.30.1) (Gopalakrishnan, 695 
2019) and flowCore (v1.50.0) (Hahne et al., 2009) Bioconductor packages. The signal of each 696 
marker in each event was normalized to the signal from the 191Ir DNA channel or 697 
appropriate total protein channel within that event. Normalized ratios were then scaled to 698 
the median 191Ir DNA or appropriate total protein signal from one selected sample for 699 
visualization purposes. 700 
 701 
To test for differential abundances, mass cytometry data from experiment 2 was processed 702 
using the ncdfFlow (v2.30.1), flowCore (v.1.50.0) and cydar (v1.8.0) (A. T. L. Lun et al., 2017) 703 
Bioconductor Packages in R. A logicle transformation (default parameters except w=0.1) was 704 
applied to raw intensity data. Data from the two batches were range-normalized based on 705 
the 4 samples that were included in both batches using the normalizeBatch function (with 706 
parameters p=0.001, fix.zero=TRUE). After normalization, one technical replicate from each 707 
of these four repeated samples was carried forward for analysis. All samples were then 708 
pooled before constructing the sequential gating strategy: removal of residual EQ beads, 709 
removal of events with high event length, retaining events with a single cell-equivalent of 710 
DNA, removal of dead cells, removal of cells with TCRE signal more than 5 MAD below the 711 
median, and removal of cells with CD8 signal more than 5 MAD below the median. Cells 712 
from each sample were down-sampled to the number in the smallest sample (10,982). Only 713 
signalling proteins and selected surface markers were included in differential abundance 714 
testing to avoid invariant and non-biological markers: pSTAT5, pAKT, pSLP76, pLCK, IκBα, 715 
pPLCγ1, pERK1/2, pZAP70, pS6, CD8α, CD44, CD25, TCRE, CD45.  716 
 717 
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To test for differential abundance of cells with any combinatorial phenotype, agnostic to 718 
cellular density or clustering patterns, we employed cytometry differential abundance 719 
testing in R (cydar, (A. T. L. Lun et al., 2017)). This method takes advantage of the consistent 720 
staining achieved with sample barcoding, along with the count-based nature of single cell 721 
data, to find regions of the high-dimensional marker space occupied significantly more or 722 
less frequently by cells from a particular condition. This is achieved by filling the marker 723 
space with hyperspheres, comparing cellular abundances within each hypersphere across 724 
conditions, and controlling the false discovery rate across the marker space. Cells were 725 
assigned to hyperspheres and counted using the prepareCellData, neighborDistances, and 726 
countCells functions from cydar (default parameters except countCells tol=0.4 and 727 
downsample=200). Hyperspheres were included in differential abundance analysis if they 728 
contained more than 50 cells on average. Differential abundance was assessed using the 729 
edgeR (v3.26.8) Bioconductor package (A. T. Lun et al., 2016; Robinson et al., 2010) with a 730 
robust quasi-likelihood GLM fit (A. T. L. Lun et al., 2017) including the biological replicate of 731 
origin as a blocking factor for each sample in an analysis of deviance test to identify 732 
hyperspheres that changed in abundance in any stimulation condition compared to the 733 
unstimulated control. The spatial FDR was controlled at 0.05 to define significantly 734 
differentially abundant hyperspheres. See Supplementary File 5 for full summary statistics 735 
from differential abundance testing.  736 
 737 
For trajectory analysis, each biological replicate was analysed separately. A logicle 738 
transformation (default parameters except w=0.1) was applied to raw intensity data. Cells 739 
within each replicate were then gated using the sequential strategy described above. The 740 
MAD threshold for TCRE+ cells was relaxed in gating biological replicates from experiment 1 741 
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due to a wider distribution in this dataset. To construct trajectories, equal numbers of cells 742 
stimulated by each ovalbumin-derived ligand were pooled with unstimulated cells. This 743 
created one sample per ligand (N4, T4 and G4) per biological replicate from which to 744 
construct trajectories. For each trajectory, cells were ordered by intensity of pS6 as this 745 
marker was observed to increase with activation over real time. Colouring cells by real time 746 
point confirmed enrichment of cells sampled at early times at the beginning of the 747 
trajectory and later times at the end (Figure 5 – figure supplement 1a). To generate plots in 748 
Figure 5 - figure supplements 1b-c, a loess curve was fitted to intensity measurements of 749 
the indicated markers across 2000 randomly sampled cells from each trajectory (span = 0.2). 750 
To determine the trajectory interval in which each activation event started, trajectories 751 
were downsampled to 5000 cells each, and a sliding window encompassing 5 % of the 752 
trajectory was established to move across the trajectory from least to most activated in 753 
steps of 1 %. The first window in which the mean intensity of cells was more than one 754 
standard deviation away from the mean intensity in the starting window was deemed the 755 
initiation of the activation event. Events that displayed a shift in mean intensity across the 756 
trajectory but fell short of the threshold (CD44 under G4 stimulation), were considered to 757 
be last in the ordering. If more than one activation event failed to meet this threshold in a 758 
given trajectory, or if two events shared an initiation window, it was not possible to robustly 759 
declare the order. The probability of achieving orders of signalling events shared to the 760 
observed extent or more between each pair of trajectories was then computed by 761 
comparing the mean-squared-distance (MSD) between the orders in trajectory 1 and 762 
trajectory 2 to a distribution of MSDs between the orders in trajectory 1 and permuted 763 
orderings of trajectory 2. Both biological replicates from experiment 2 that contained all 764 
time-points revealed identical orders of activation events across all stimulation conditions. 765 
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The two biological replicates in experiment 1 that included 0, 1 and 2 hours of stimulation 766 
also revealed the same order of activation of pS6 and pERK, while pSTAT5 and CD44 were 767 
not sufficiently activated by 2 hours to determine their ordering. It was not possible to order 768 
events in the remaining biological replicates from experiment 1 that included only 1 769 
stimulated timepoint.  770 
 771 
Flow cytometry 772 
 773 
To test BMDC maturation, cells were stained with live-dead marker (Zombie-NIR or Zombie-774 
Aqua Fixable Viability Kit, Biolegend) in PBS before staining in incubation buffer (1 % FBS in 775 
PBS) with FCR (FC receptor) blocking antibody (Biolegend, clone 93) and antibodies against 776 
CD11c, MHC II, CD80, CD86, CD40 and ICAM1 (Supplementary File 2). Cells were acquired on 777 
a BD LSRFortessa. Data were analysed in FlowJo (v10) gating on single, live cells. BMDCs 778 
were consistently > 90 % CD11c+ and MHC II+ (Figure 7 – figure supplement 1b). To measure 779 
CD80 and ICAM-1 expression on activated T cells, T cells were stained with live-dead marker 780 
(Zombie-NIR Fixable Viability Kit, Biolegend) and antibodies against CD80 and ICAM1 in the 781 
same way. 782 
 783 
To test the impact of inhibiting the MEK and mTOR pathways on cell proliferation (Figure 3 – 784 
figure supplement 3g), cells were stained with eBioscience Cell Proliferation Dye eFluor-450 785 
(ThermoFisher), pre-treated for 2 hours with MEK162 (1 µM and 5 µM), rapamycin (200 nM) 786 
or combined MEK162 (1 µM or 5 µM) and rapamycin (200 nM), and stimulated with 1 µM 787 
N4 or NP68 peptides for 2 days. Cells were then stained with live-dead marker (Zombie-NIR 788 
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Fixable Viability Kit, Biolegend) and acquired on a BD LSRFortessa and data analysed in 789 
FlowJo (v10) gating on live, single cells.  790 
 791 
Phosphoflow cytometry 792 
 793 
For phosphoflow cytometry experiments in Figure 2 - figure supplement 1, Figure 3b-d, 794 
Figure 3 - figure supplements 2 and 3, and Figure 7, after stimulation, cells were fixed in 4 % 795 
paraformaldehyde (Electron Microscopy Sciences) at room temperature for 15 minutes and 796 
washed in PBS.  Cells were permeabilized with 90 % ice-cold methanol (Fisher Scientific) for 797 
30 minutes on ice or overnight at -20 °C.  Cells were washed in PBS and resuspended in 100 798 
µL incubation buffer containing FCR blocking antibody (Biolegend, clone 93), stained with 799 
the primary antibodies of interest (Supplementary File 2), and incubated for 1 hour at room 800 
temperature. In cases where the primary antibody was not conjugated to a fluorophore, the 801 
cells were then washed, resuspended in 100 µL incubation buffer containing FCR blocking 802 
antibody and secondary antibody (Supplementary File 2) and incubated for 30 minutes at 803 
room temperature. Cells were washed in incubation buffer prior to data acquisition on a BD 804 
LSRFortessa.  Data were analysed in FlowJo (v10) gating on single, live cells. 805 
 806 
To test the impact of titrating peptides on the phosphorylation of ERK and S6 (Figure 2 – 807 
figure supplement 1), cells stained with live-dead marker (Zombie-NIR Fixable Viability Kit, 808 
Biolegend) were stimulated with N4, T4, G4 and NP68 peptides at concentrations of 10 nM, 809 
100 nM and 1 µM for 2 and 4 hours.  810 
 811 
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To test the impact of adding or withholding exogenous IL2 on phosphorylation of STAT5, S6, 812 
ERK, and AKT, and degradation of INBD (Figure 3 – figure supplement 2), cells stained with a 813 
live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) were stimulated with 1 µM of 814 
peptides for 4 hours.  815 
 816 
To test the impact of inhibiting the MEK/ERK and mTOR/S6 pathways (Figure 3b-d, figure 817 
supplement 3d-f), cells stained with live-dead marker (Zombie-NIR Fixable Viability Kit, 818 
Biolegend) were pre-treated with the MEK inhibitor MEK162 (binimetinib/ARRY-162/ARRY-819 
438162, Selleckchem), mTOR inhibitor rapamycin (Sigma-Aldrich) or combined MEK162 and 820 
rapamycin for 2 hours. MEK162 was added at 0.5 µM, 1 µM and 5 µM, rapamycin was 821 
added at 20 nM, 200 nM and 2 µM.  For combined drug treatments, MEK162 was added at 822 
0.5 µM, 1 µM and 5 µM with rapamycin at 200 nM.  DMSO as a vehicle control was added at 823 
1:1000, corresponding to the amount in the 200 nM dose of rapamycin and the 1 µM dose 824 
of MEK162.  Cells were stimulated with 1 µM of N4 or NP68 peptides for 4 hours.  825 
 826 
To test naïve T cell stimulation with peptide-loaded BMDCs, T cells were stained with live-827 
dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) before co-culture with BMDCs. 828 
 829 
Combined phosphoflow with RNA flow cytometry 830 
 831 
To combine phosphoflow with RNA flow cytometry (Figure 6 and figure supplement 1b-c), 832 
purified naïve CD8D+ T cells were stained using a live-dead marker (Zombie Aqua Fixable 833 
Viability Kit, Biolegend).  To achieve a sufficient number of cells, isolated naïve CD8+ T cells 834 
from three age- and gender-matched mice were pooled for each biological replicate. Cells 835 
 36 
 
were stimulated for 0-6 hours with 1 µM N4, T4, G4, or NP68 peptides.  At the end of 836 
stimulation, cells were immediately moved on to ice and washed with cold PBS. Cells were 837 
fixed and permeabilised using the Primeflow RNA Assay Kit (ThermoFisher Scientific), 838 
blocked with FCR blocking reagent (Biolegend, clone 93) and stained with antibodies against 839 
pS6[S235/236] (BD Biosciences clone N7-548) for 30 minutes. Cells were stained with the 840 
following PrimeFlow probe sets (Thermofisher Scientific): Nr4a1 AF647 (Type1, VB1-12484-841 
204), Irf8 AF750 (Type 6, VB6-3197312-210), and Rpl39 AF488 (Type 4, VB4-3120826-204) as 842 
a control. The use of Rpl39 as a control gene was previously described in naïve and recently 843 
activated CD8+ T cells (Richard et al., 2018). Cells were acquired on a BD LSRForessa and 844 
analysed in FlowJo (v10). Cells were gated on single, live cells that expressed Rpl39, to 845 
ensure cells were permeabilized and probes hybridized and amplified.  846 
 847 
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Code availability statement 848 
 849 
Analysis code for mass cytometry data is available at: 850 
https://github.com/MarioniLab/SignallingMassCytoStimStrength 851 
 852 
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Data availability statement 854 
 855 
Mass cytometry data are available in the Flow Repository, accession numbers FR-FCM-Z2CX 856 
and FR-FCM-Z2CP.  857 
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Figure Legends: 1226 
 1227 
Figure 1: Diagrammatic representation of TCR signalling pathways measured by mass 1228 
cytometry panel 1229 
 1230 
Cartoon depicts the TCR-related signalling pathways examined in this study in our minimal 1231 
stimulation system wherein T cells present antigen to each other. Solid lines indicate 1232 
evidence of direct and dotted lines suggested or indirect interaction. Signalling proteins and 1233 
post-translational modifications directly measured by mass cytometry antibodies are 1234 
outlined in purple. The mass cytometry panel also profiled surface proteins TCRE, CD8D, 1235 
CD45, CD25 (IL2RD), and CD44. 1236 
 1237 
Figure 2. Mass cytometry measurements of signalling events in singlet and doublet events.   1238 
 1239 
a) Naïve CD8+ T cells were stimulated with 1 PM peptides of various potencies for 0, 1, 2, 4 1240 
and 6h before profiling by mass cytometry. Histograms depict pS6 signal. b) Bubble plots of 1241 
all signalling molecules after stimulation as in (a) in mass cytometry events with 1 or 2 cell-1242 
equivalents of DNA (singlets or doublets, respectively). The size of the bubbles denotes the 1243 
percentage of positive cells, and the colour denotes the centred and scaled median intensity 1244 
of each positive fraction. Results are representative of cells from 6 biological replicates 1245 
measured in 2 independent experiments as detailed in Supplementary File 1. 1246 
 1247 
The following figure supplements are available for figure 2. 1248 
Figure 2- figure supplement 1. Titrating peptide concentration. 1249 
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Figure 2- figure supplement 2. Gating based on DNA content and comparison of signalling 1250 
markers. 1251 
 1252 
Figure 3. Kinetics of selected signalling proteins and impact of MEK and mTOR pathway 1253 
inhibitors on T cell activation parameters. 1254 
 1255 
a) The percentage of cells positive for each marker is plotted against time. Results depict 1256 
combined data from 6 biological replicates measured in 2 independent experiments as 1257 
detailed in Supplementary File 1. Points represent the mean and error bars depict the SD. 1258 
Data underlying plots are provided in Supplementary File 5. b-c) Flow cytometry 1259 
measurements of pS6[S235/236] and pERK1/2 after 2h of pre-treatment with DMSO vehicle 1260 
control, rapamycin (Rapa) 200 nM, MEK162 (MEK) 0.5 μM, 1 μM and 5 μM, or combined 1261 
rapamycin with MEK162 (R + M), followed by 4h stimulation with 1 μM N4 or NP68 1262 
peptides. Results are representative of 3 independent experiments. d) The fraction of pS6+ 1263 
cells in N4-stimulated conditions with the indicated inhibitor treatments versus DMSO (top). 1264 
The median fluorescent intensity of pS6 among pS6+ cells in N4-stimulated conditions with 1265 
the indicated inhibitor treatments (bottom). Lines represent the median. Results depict 1266 
combined data from 3 independent experiments. 1267 
 1268 
The following figure supplements are available for figure 3. 1269 
Figure 3- figure supplement 1. Kinetics of total protein levels and surface markers. 1270 
Figure 3- figure supplement 2. Kinetics of pSTAT5, pLCK and pSLP76 signalling proteins, and 1271 
testing the impact of IL2. 1272 
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Figure 3- figure supplement 3. pERK and pS6 distributions and additional MEK and mTOR 1273 
inhibition data.  1274 
 1275 
Figure 4. Examination of multi-dimensional phenotypes in mass cytometry signalling data. 1276 
 1277 
a) Mass cytometry stimulation time courses were further investigated for multidimensional 1278 
phenotypes that changed in abundance with stimulation. Analysis was run on 2 multiplexed 1279 
biological replicates as described in Methods. Phenotypic hyperspheres were defined within 1280 
the multidimensional mass cytometry space and abundances of cells from each condition 1281 
enumerated within each hypersphere. Each column in the heatmap represents an individual 1282 
hypersphere. At the top of the heatmap, rows correspond to mass cytometry marker 1283 
measurements with colour depicting the intensity of each marker in each hypersphere. 1284 
Clustering by Pearson correlation was performed on these hypersphere marker intensity 1285 
measurements. At the bottom of the heatmap, rows correspond to stimulation conditions 1286 
with colour depicting the binned log2-fold change in cellular abundance in stimulated versus 1287 
unstimulated conditions within each hypersphere. ns = hyperspheres that did not 1288 
significantly change in abundance. Phenotypic clusters of interest, A, A’, B, B’, are indicated 1289 
in both CD44+ and CD44- populations by coloured highlighting of the dendrogram. Statistics 1290 
underlying the heatmap are provided in Supplementary File 5. b) Percentages of cells 1291 
exhibiting A, A’, B, and B’ phenotypes in mass cytometry measurements. Results are 1292 
combined data from 6 biological replicates measured in 2 independent experiments as 1293 
detailed in Supplementary File 1. Points represent the mean and error bars depict the SD.  1294 
Data underlying plots are provided in Supplementary File 5. c) Phenotypes as in (b) further 1295 
sub-divided by CD44 expression. 1296 
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 1297 
The following figure supplements are available for figure 4. 1298 
Figure 4- figure supplement 1. t-SNE visualization of significantly differentially abundant 1299 
hyperspheres. 1300 
Figure 4- figure supplement 2. Heatmap of populations in Figure 4c additionally including 1301 
pS6- populations. 1302 
 1303 
Figure 5. Cartoon Model 1304 
 1305 
Cartoon depicts the kinetics of the 4 main signalling phenotypes in cells stimulated with 1306 
ligands of varying potencies (N4, T4, G4) over time from data in Figures 3A and 4A-B (note 1307 
the transient pERK+ populations, even with G4). Black outlines indicate CD44+ populations.  1308 
 1309 
The following figure supplements are available for figure 5. 1310 
Figure 5- figure supplement 1. Activation trajectories for examining the order of signalling 1311 
events. 1312 
 1313 
Figure 6. Simultaneous measurement of phosphorylation of S6 and mRNA expression of 1314 
transcription factors Nr4a1 and Irf8. 1315 
 1316 
a) Combined phosphoflow cytometry of pS6 and RNA flow cytometry of Nr4a1 and Irf8 1317 
transcripts in naïve OT-I CD8+ T cells stimulated with N4, T4, G4 or NP68 peptides for 2h, 1318 
gated on single live cells in which the control gene Rpl39 was detected. b) Frequency of 1319 
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phenotypes depicted in (a) after stimulation for 1, 2, 4 or 6h. Data are representative of 3 1320 
independent experiments.  1321 
 1322 
The following figure supplements are available for figure 6. 1323 
Figure 6- figure supplement 1. RNA flow cytometry gating strategy and histograms. 1324 
 1325 
Figure 7. Signalling phenotypes in T cells stimulated with peptide-pulsed APCs 1326 
 1327 
a) Naïve CD8+ T cells were stimulated with mature BMDCs loaded with peptides of various 1328 
potencies for 1, 2, 4 and 6h before profiling by flow cytometry. The percentage of cells 1329 
positive for each marker is plotted against time. Results depict combined data from 3 1330 
independent experiments. Points represent the mean and error bars depict the SD. b) 1331 
Example flow cytometry data from (a) of pERK1/2 and pS6 measured at 1 and 6h. 1332 
 1333 
Figure 7 – source data 1.  Data underlying plots in Figure 7a. 1334 
 1335 
The following figure supplements are available for figure 7. 1336 
Figure 7- figure supplement 1. Expression of adhesion and costimulatory molecules on T 1337 
cells and BMDCs. 1338 
 1339 
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Figure Supplement Legends 1340 
 1341 
Figure 2- figure supplement 1: Titrating peptide concentration  1342 
 1343 
a) Flow cytometry measurements of pS6 and pERK after 2 or 4h of simulation with 10 nM, 1344 
100 nM or 1 μM of N4, T4, G4 or NP68 peptides. Results are representative of 3 biological 1345 
replicates.  1346 
 1347 
Figure 2- figure supplement 2: Gating based on DNA content and comparison of signalling 1348 
markers 1349 
 1350 
a) Gating strategy used to select mass cytometry events containing one or two cell-1351 
equivalents of DNA from mass cytometry data in Figure 2. b) Percentages of mass cytometry 1352 
events deemed doublets (2 cell-equivalents of DNA). Plot depicts mean and standard 1353 
deviation of 6 biological replicates measured in 2 independent experiments as detailed in 1354 
Supplementary File 1. c-d) Expression of total (c) and phosphorylated (d) protein 1355 
measurements in cells stimulated with N4 peptide for 1h, gated on singlets (red) versus 1356 
doublets (blue). Data is representative of 6 biological replicates measured in 2 independent 1357 
experiments. e) As (d) after normalization of signalling molecules to total DNA levels.   1358 
 1359 
Figure 3- figure supplement 1: Kinetics of total protein levels and surface markers 1360 
 1361 
The median intensity of proteins measured by mass cytometry under stimulation with 1362 
ligands of various potencies over time. Points represent the mean and error bars depict the 1363 
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SD. Results depict combined data from 6 biological replicates measured in 2 independent 1364 
experiments as detailed in Supplementary File 1.  1365 
 1366 
Figure 3 – figure supplement 2: Kinetics of pSTAT5, pLCK and pSLP76 signalling proteins 1367 
and testing the impact of IL2. 1368 
 1369 
a) As Figure 3a for pSTAT5, pLCK and pSLP76.  Plots depict combined data from 6 biological 1370 
replicates measured in 2 independent experiments as detailed in Supplementary File 1. 1371 
Points represent the mean and error bars depict the SD. Data underlying plots are provided 1372 
in Supplementary File 1. b) Flow cytometry measurements of pSTAT5, pS6[S235/236] 1373 
pERK1/2, pAKT and INBD, stimulated with peptides of various potencies for 4h, in the 1374 
presence or absence of IL2. Results depict combined data from 3 biological replicates 1375 
measured in 2-3 independent experiments. Bar charts represent the mean and error bars 1376 
depict the SD. 1377 
 1378 
Figure 3 – figure supplement 3: pERK and pS6 distributions and additional MEK and mTOR 1379 
inhibition data   1380 
 1381 
a) Cells were gated on pERK1/2 positive and negative populations. Within these 1382 
populations, the median marker intensity was calculated at each timepoint in each 1383 
condition. b) As (a) for pS6[S235/S236]. c) As (b) after normalization of pS6 intensity to total 1384 
S6 intensity within each cell. a-c) Plots are representative of 6 biological replicates measured 1385 
in 2 independent experiments as detailed in Supplementary File 1. d) As Figure 3b, 1386 
measuring pERK1/2. e) Flow cytometry measurements of pS6[S235/236] after stimulation in 1387 
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the presence of the indicated concentrations of rapamycin. f) The median fluorescent 1388 
intensity of CD44 among live cells in N4-stimulated conditions with the indicated inhibitor 1389 
treatments. Results depict combined data from 3 independent experiments. Lines represent 1390 
the mean. g) 2-day proliferation assay of cells treated as in (d-f) measured using Cell 1391 
Proliferation Dye eFluor450. d,e,g) Results are representative of 3 biological replicates from 1392 
2-3 independent experiments.  1393 
 1394 
Figure 4 – figure supplement 1: t-SNE visualization of significantly differentially abundant 1395 
hyperspheres 1396 
 1397 
a) tSNE plots depict hyperspheres from Figure 4a. Colour indicates log2-fold change of 1398 
cellular abundance in each stimulated condition versus unstimulated for each hypersphere. 1399 
b) As (a) with colour indicating the median intensity of each marker within each 1400 
hypersphere. Underlying data are provided in Supplementary File 5. 1401 
 1402 
Figure 4 – figure supplement 2: Heatmap of populations in Figure 4c including pS6 - 1403 
 1404 
Data from Figure 4c, additionally including pS6- phenotypes, are plotted as a heatmap. Plots 1405 
depict averages from 6 biological replicates measured in 2 independent experiments as 1406 
detailed in Supplementary File 1.  1407 
 1408 
Figure 5 – figure supplement 1: Activation trajectories for examining the order of 1409 
signalling events 1410 
 1411 
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a) Mass cytometry data was grouped by biological replicate and stimulating ligand before 1412 
constructing activation trajectories by ordering the cells according to pS6 intensity. Plots 1413 
depict 1000 randomly sampled cells from an example replicate. Colours represent real times 1414 
at which cells were sampled. b) Example of pERK1/2 intensity measurements along the 1415 
trajectories constructed in (a). c) Loess curves were fitted to intensities of the indicated 1416 
markers along the trajectories depicted in (a). Dotted lines represent the estimated 1417 
standard error from the loess fits. d) As (c) for additional signalling markers. Trajectories are 1418 
representative of the 4 biological replicates that included at least 3 time points, measured in 1419 
2 independent experiments as detailed in Supplementary File 1. 1420 
 1421 
Figure 6 – figure supplement 1: RNA flow cytometry gating strategy and histograms 1422 
 1423 
a) Single cell RNA-seq of Irf8 and Nr4a1 expression after 0-6 hours stimulation with 1 μM N4 1424 
peptide from previously published data (Richard et al., 2018), ArrayExpress E-MTAB-6051, 1425 
depicted as violin plots, with dots indicating individual cells. b) Gating strategy for combined 1426 
phosphoflow cytometry of pS6 and RNA flow cytometry: cells were gated on size, single 1427 
cells, live cells and Rpl39+ cells, before examining Nr4a1, Irf8 and pS6 with gates based on 1428 
fluorescence-minus-one stains. c) As Figure 6, histograms depict flow cytometry 1429 
measurements of Nr4a1, Irf8 and pS6 (gated on Rpl39+ cells), and the control mRNA Rpl39 1430 
(gated on live cells) over all time points measured. Data are representative of 3 independent 1431 
experiments. 1432 
 1433 
Figure 7 – figure supplement 1: Expression of adhesion and costimulatory molecules on T 1434 
cells and BMDCs 1435 
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 1436 
a) Expression of CD80 and ICAM-1 on T cells after 6 hours of stimulation with 1 μM of the 1437 
indicated peptides. Results are representative of 3 biological replicates measured in 2 1438 
independent experiments. b) Surface protein phenotyping of BMDCs before and after 1439 
maturation for 1 day with LPS. Results are representative of 5 independent experiments. 1440 
 1441 
Supplementary File Legends 1442 
 1443 
Supplementary File 1: Replicate structure  1444 
Table details independent experiments, biological replicates and, where applicable, 1445 
barcoding strategies  1446 
 1447 
Supplementary File 2: Key Resources Table 1448 
 1449 
Supplementary File 3: Antibodies for mass cytometry 1450 
 1451 
Supplementary File 4: Antibody testing and specificity 1452 
Antibody specificity tables detail experiments used to test and validate a) antibodies 1453 
targeting total proteins and b-c) signalling proteins. Tables also include relevant references 1454 
utilising these clones in knockout, knockdown, overexpression or small molecule inhibitor 1455 
experiments.  1456 
 1457 
Supplementary File 5: Mass cytometry figure underlying data 1458 
 57 
 
Tables provide means and standard deviations of kinetics curves depicted in Figures 3a, 4b-1459 
c, and Figure 3 – figure supplement 2a, as well as summary statistics from hypersphere 1460 
differential abundance testing depicted in Figure 4a and Figure 4 – figure supplement 1. 1461 
 1462 
Source Data Files 1463 
 1464 
Figure 7 – source data 1.  Data underlying plots in Figure 7a. 1465 
 1466 
 1467 
 1468 
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